According to the National Health Services (NHS), around 25-35% of patients on statin therapy suffer from increased levels of triglycerides. Elevated triglycerides in patients with controlled low density lipoprotein cholesterol (LDL-C) are known to cause cardiovascular events like heart attacks and strokes, besides a probable damage to vital organs like the brain, heart, kidneys, and eyes. Lifestyle changes, diet, and exercise may not work for all patients.
Currently, there is no treatment available to address the cardiovascular risk in patients with elevated fasting triglycerides and controlled LDL-C having statins with or without ezetimibe. The National Institute for Health and Care Excellence (NICE) conducted a double-blind randomized phase III clinical trial with 8000 patients over a period of 4.9 years in order to provide a solution n the form of a drug for people who are at risk of…
